62 related articles for article (PubMed ID: 15247158)
1. Development of sensitive immunoassays for free and total human glandular kallikrein 2.
Väisänen V; Eriksson S; Ivaska KK; Lilja H; Nurmi M; Pettersson K
Clin Chem; 2004 Sep; 50(9):1607-17. PubMed ID: 15247158
[TBL] [Abstract][Full Text] [Related]
2. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.
Thorek DL; Evans MJ; Carlsson SV; Ulmert D; Lilja H
Thromb Haemost; 2013 Sep; 110(3):484-92. PubMed ID: 23903407
[TBL] [Abstract][Full Text] [Related]
4. Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
Macagno A; Athanasiou A; Wittig A; Huber R; Weber S; Keller T; Rhiel M; Golding B; Schiess R
PLoS One; 2020; 15(5):e0233442. PubMed ID: 32421745
[TBL] [Abstract][Full Text] [Related]
5. Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine.
Fredsøe J; Rasmussen M; Tin AL; Vickers AJ; Borre M; Sørensen KD; Lilja H
Sci Rep; 2022 Sep; 12(1):15193. PubMed ID: 36071094
[TBL] [Abstract][Full Text] [Related]
6. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
Bicak M; Lückerath K; Kalidindi T; Phelps ME; Strand SE; Morris MJ; Radu CG; Damoiseaux R; Peltola MT; Peekhaus N; Ho A; Veach D; Malmborg Hager AC; Larson SM; Lilja H; McDevitt MR; Klein RJ; Ulmert D
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15172-15181. PubMed ID: 32532924
[TBL] [Abstract][Full Text] [Related]
7. Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.
Thorek DLJ; Ku AT; Mitsiades N; Veach D; Watson PA; Metha D; Strand SE; Sharma SK; Lewis JS; Abou DS; Lilja HG; Larson SM; McDevitt MR; Ulmert D
Clin Cancer Res; 2019 Jan; 25(2):881-891. PubMed ID: 30254080
[TBL] [Abstract][Full Text] [Related]
8. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
[TBL] [Abstract][Full Text] [Related]
9. Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival.
Guerrico AG; Hillman D; Karnes J; Davis B; Gaston S; Klee G
J Circ Biomark; 2017; 6():1849454417720151. PubMed ID: 28936267
[TBL] [Abstract][Full Text] [Related]
10. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.
Thorek DL; Watson PA; Lee SG; Ku AT; Bournazos S; Braun K; Kim K; Sjöström K; Doran MG; Lamminmäki U; Santos E; Veach D; Turkekul M; Casey E; Lewis JS; Abou DS; van Voss MR; Scardino PT; Strand SE; Alpaugh ML; Scher HI; Lilja H; Larson SM; Ulmert D
Sci Transl Med; 2016 Nov; 8(367):367ra167. PubMed ID: 27903863
[TBL] [Abstract][Full Text] [Related]
11. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.
Kim EH; Andriole GL; Crawford ED; Sjoberg DD; Assel M; Vickers AJ; Lilja H
J Urol; 2017 Apr; 197(4):1041-1047. PubMed ID: 27810449
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.
Vilhelmsson Timmermand O; Larsson E; Ulmert D; Tran TA; Strand S
EJNMMI Res; 2016 Dec; 6(1):27. PubMed ID: 26983637
[TBL] [Abstract][Full Text] [Related]
13. Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.
Timmermand OV; Ulmert D; Evans-Axelsson S; Pettersson K; Bjartell A; Lilja H; Strand SE; Tran TA
EJNMMI Res; 2014 Dec; 4(1):51. PubMed ID: 26116115
[TBL] [Abstract][Full Text] [Related]
14. A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.
Lee SW; Hosokawa K; Kim S; Jeong OC; Lilja H; Laurell T; Maeda M
Sensors (Basel); 2015 May; 15(5):11972-87. PubMed ID: 26007739
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.
Sävblom C; Halldén C; Cronin AM; Säll T; Savage C; Vertosick EA; Klein RJ; Giwercman A; Lilja H
Clin Chem; 2014 Mar; 60(3):490-9. PubMed ID: 24270797
[TBL] [Abstract][Full Text] [Related]
16. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
Carlsson SV; Peltola MT; Sjoberg D; Schröder FH; Hugosson J; Pettersson K; Scardino PT; Vickers AJ; Lilja H; Roobol MJ
BJU Int; 2013 Sep; 112(5):602-9. PubMed ID: 23448270
[TBL] [Abstract][Full Text] [Related]
17. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
Ulmert D; Vickers AJ; Scher HI; Becker C; Iversen P; Frankel D; Jensen JK; Olesen TK; Lilja H
Clin Chem Lab Med; 2012 Nov; 50(11):1993-8. PubMed ID: 22718641
[TBL] [Abstract][Full Text] [Related]
18. Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).
Peltola MT; Niemelä P; Alanen K; Nurmi M; Lilja H; Pettersson K
J Immunol Methods; 2011 Jun; 369(1-2):74-80. PubMed ID: 21554885
[TBL] [Abstract][Full Text] [Related]
19. Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
Christensson A; Bruun L; Björk T; Cronin AM; Vickers AJ; Savage CJ; Lilja H
BJU Int; 2011 Jun; 107(11):1769-74. PubMed ID: 20955263
[TBL] [Abstract][Full Text] [Related]
20. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
